CD19 and Castleman disease: Additionally, existing case reports have shown that tocilizumab has significant efficacy in AIHA secondary to SLE or Castleman’s disease, which can improve the hemolytic symptoms of patients and reduce the dosage of glucocorticoid25,26.Proportion of CD80+/CD5+ CD19+ B cells and CD80+/CD5-CD19+ B cells in IL-6 + toc stimulation group was lower than that in IL-6 stimulation group.